North America Vascular Stent Market (2025-2035) Analysis
The North America Vascular Stent Market is forecasted to grow significantly between 2025 and 2035, driven by the increasing prevalence of cardiovascular diseases, technological advancements in stent design, and the rising adoption of minimally invasive surgeries. The market encompasses various stent types including coronary, peripheral, and EVAR stent grafts, and finds application in treating coronary artery diseases, peripheral artery diseases, aneurysms, and others. The distribution channels include hospitals, ambulatory surgical centers, clinics, retail, and online pharmacies, with the U.S. leading market share in the region.
Latest Market Dynamics
Key Drivers
- Rising incidence of cardiovascular diseases in North America, driving substantial demand for vascular stents. For example, Medtronic plc has expanded its stent portfolio catering to coronary and peripheral artery diseases, reflecting this underlying trend.
- Growing preference for minimally invasive procedures, leading to higher vascular stent usage. Boston Scientific Corporation, for instance, reported increased adoption of its drug-eluting stents due to decreased post-surgical complications and shorter patient recovery times.
Key Trends
- Rapid shift towards drug-eluting and bioabsorbable stents, offering enhanced clinical outcomes and reduced restenosis risks. Companies like Abbott Laboratories continue to launch next-generation drug-eluting stents with improved performance characteristics.
- Adoption of advanced imaging and AI-driven diagnostic integration into stent procedures, enabling precision placement and improved patient success rates. Terumo Corporation has invested in digital health infrastructure supporting such tech enhancements.
Key Opportunities
- Significant growth potential in underserved patient segments, such as those with complex vascular anatomies. Cook Medical is developing niche stent solutions to address these demands.
- Expansion of stent usage in outpatient and ambulatory surgical settings. Cardinal Health reports rising stent sales through ambulatory surgery centers as patients seek quicker and less invasive treatment options.
Key Challenges
- Stringent regulatory requirements and reimbursement hurdles, leading to delayed product launches. Boston Scientific Corporation recently overcame U.S. FDA regulatory delays in new stent approvals.
- Increasing market competition from low-cost manufacturers, particularly across the U.S. and Canada. MicroPort Scientific Corporation is actively expanding its presence with competitively priced stent solutions.
Key Restraints
- High procedural costs and limited access in certain rural North American regions. Endologix LLC is working to address affordability through targeted pricing strategies.
- Incidences of post-operative complications, such as thrombosis and in-stent restenosis, which curb broader adoption. Biotronik SE & Co. KG is actively investing in research to minimize such risks.
North America Vascular Stent Market Share (%) by Type, 2025
In 2025, Coronary Stents dominate the North America vascular stent market, driven by high prevalence of coronary artery disease and continued innovation in drug-eluting and bioabsorbable technologies. Peripheral stents follow, supported by rising cases of peripheral artery diseases. EVAR stent grafts serve the aneurysm segment, while other niche types fill specific clinical gaps. The overall type composition indicates substantial ongoing demand for advanced stenting technologies targeting diverse arterial segments across the region.
North America Vascular Stent Market Share (%) by Application, 2025
The application breakdown in 2025 shows coronary artery diseases as the largest segment, corresponding with North America’s high incidence of heart conditions. Peripheral artery diseases also account for a sizeable market share, propelled by lifestyle factors and aging demographics. Aneurysm treatment segment steadily grows, while stroke and other niche vascular interventions represent a smaller, yet important component for specialized care. The application trend highlights the critical clinical role stents serve across multiple vascular disorders.
North America Vascular Stent Market Revenue (USD Million), 2020-2035
The North America vascular stent market is projected to grow from $6,100 million in 2020 to $11,900 million by 2035. The U.S. contributes the largest revenue share due to advanced healthcare infrastructure and rapid adoption of next-generation stenting technologies. Year-on-year growth reflects both rising cardiovascular disease burden and steady introduction of minimally invasive stenting options. Investments in digital diagnostics and procedural efficiency are anticipated to further boost the region’s vascular stent market value through 2035.
North America Vascular Stent Market YoY Growth (%), 2020-2035
YoY growth in the North America vascular stent market exhibits stable, single-digit gains, averaging 4.2% in the 2020-2025 period and gradually moderating toward 3.2% by 2035 as the market matures. Early surges are driven by technological advancements and swift regulatory approvals, while competitive pressures and market saturation lead to steady, sustained expansion in the decade ahead.
North America Vascular Stent Market Share (%) by Region, 2025
The U.S. holds the lion’s share of the North America market at 83%, owing to its robust healthcare ecosystem and greater per capita expenditure on advanced treatments. Canada follows at 10%, benefitting from universal healthcare and increasing cardiovascular interventions. Mexico’s share stands at 7%, rapidly growing as healthcare access improves. This regional distribution reflects both mature and emerging opportunities for stent manufacturers across North America.
North America Vascular Stent Market Major Players' Share (%), 2025
Abbott Laboratories leads the North American vascular stent market with significant investments in R&D and new product launches. Boston Scientific Corporation and Medtronic plc follow closely, leveraging their extensive distribution networks. Other established names include B. Braun and Terumo, who are expanding their influence through innovation and strategic partnerships. The top five players account for a majority share of the competitive landscape in 2025.
North America Vascular Stent Market Buyers Share (%), 2025
In 2025, hospitals remain the principal buyers of vascular stents, making up 59% of the market, thanks to high patient volumes and ability to handle complex cases. Ambulatory surgical centers are capturing a growing share at 18%, reflecting the trend toward outpatient procedures. Clinics and other buyers make up the remaining portion, advancing vascular stent penetration outside of major hospital systems as procedural simplicity rises.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 7600 |
| Regions | US, Canada, Mexico |
| Segments | Coronary Stents, Peripheral Stents, EVAR Stent Grafts, Drug Eluting Stents, Bare Metal Stents, Others; Coronary Artery Diseases, Peripheral Artery Diseases, Aneurysm, Stroke, Carotid Artery Disease, Others |
| Players | Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, B. Braun Melsungen AG, Terumo Corporation, Cook Medical, Cardinal Health, C.R. Bard (Becton, Dickinson and Company), MicroPort Scientific Corporation, Biotronik SE & Co. KG, Endologix LLC, Gore Medical, Cordis (Cardinal Health), Lombard Medical, Others |
Key Recent Developments
- June 2024: Abbott Laboratories announced the launch of its new-generation drug eluting stent, delivering enhanced outcomes for complex coronary lesions.
- July 2024: Medtronic plc received FDA approval for its next-gen self-expanding peripheral stent, expanding access for critical limb ischemia patients.
- August 2024: Boston Scientific Corporation completed the acquisition of a digital health startup to improve stent-patient follow-up care using AI-powered platforms.
- September 2024: Terumo Corporation expanded its North America distribution network, focusing on balloon-expandable and bioabsorbable stent segments.
- October 2024: Cook Medical reported successful completion of a large-scale clinical trial for its latest EVAR stent graft technology, with publication of favorable results.
